Biochemical effect of resistance mutations against synergistic inhibitors of RSV RNA polymerase

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Deval, Jerome ^a   Fung, Amy ^a   Stevens, Sarah K ^a   Jordan, Paul C ^a   Gromova, Tatiana ^a   Taylor, Joshua S ^a   Hong, Jin ^a   Meng, Jia ^a   Wang, Guangyi ^a   Dyatkina, Natalia ^a   Prhavc, Marija ^a   Symons, Julian A ^a   Beigelman, Leo ^a  

^a Alios BioPharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALS 8112; ANTIVIRUS AGENT; AZ 27; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA POLYMERASE; UNCLASSIFIED DRUG; 2'-FLUORO-4'-CHLOROMETHYL-CYTIDINE TRIPHOSPHATE; AZ-27 COMPOUND; BENZAZEPINE DERIVATIVE; CYTIDINE TRIPHOSPHATE; DNA DIRECTED RNA POLYMERASE; DRUG COMBINATION; NICOTINAMIDE; RECOMBINANT PROTEIN; VIRAL PROTEIN; VIRUS RNA;

AMINO ACID ANALYSIS; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; PHENOTYPE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; RESPIRATORY SYNCYTIAL VIRUS INFECTION; STRUCTURAL HOMOLOGY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; BIOSYNTHESIS; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; EPITHELIUM CELL; GENE EXPRESSION; GENETICS; METABOLISM; POINT MUTATION; TUMOR CELL LINE; VIROLOGY;

ANTIVIRAL AGENTS; BENZAZEPINES; CELL LINE, TUMOR; CYTIDINE TRIPHOSPHATE; DNA-DIRECTED RNA POLYMERASES; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; EPITHELIAL CELLS; GENE EXPRESSION; HUMANS; NIACINAMIDE; POINT MUTATION; RECOMBINANT PROTEINS; RNA, VIRAL; VIRAL PROTEINS;

EID: 84968830302     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0154097     Document Type: Article

References (35)

1. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., et al. (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysisLancet 375: 1545-1555 10.1016/S0140-6736(10)60206-1 PMID: 20399493
2. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. (2003) Mortality associated with influenza and respiratory syncytial virus in the United StatesJAMA 289: 179-186 PMID: 12517228
3. Hall C.B., Weinberg G.A., Iwane M.K., Blumkin A.K., Edwards K.M., Staat M.A., et al. (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360: 588-598 10.1056/NEJMoa0804877 PMID: 19196675
4. Mazur N.I., Martinon-Torres F., Baraldi E., Fauroux B., Greenough A., Heikkinen T., et al. (2015) Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeuticsLancet Respir Med 3: 888-900 10.1016/S2213-2600(15)00255-6 PMID: 26411809
5. Empey K.M., Peebles RS Jr., Kolls J.K. (2010) Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis 50: 1258-1267 10.1086/651603 PMID: 20235830
6. DeVincenzo J.P., McClure M.W., Symons J.A., Fathi H., Westland C., Chanda S., et al. (2015) Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study. N Engl J Med 373: 2048-2058 10.1056/NEJMoa1413275 PMID: 26580997
7. Wang G., Deval J., Hong J., Dyatkina N., Prhavc M., Taylor J., et al. (2015) Discovery of 4′-chloromethyl-2′-deoxy-3′,5′-di-O-isobutyryl-2′-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem 58: 1862-1878 10.1021/jm5017279 PMID: 25667954
8. Deval J., Hong J., Wang G., Taylor J., Smith L.K., Fung A., et al. (2015) Molecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2′-Fluoro-4′-Chloromethyl-Cytidine TriphosphatePLoS Pathog 11: e1004995 10.1371/journal.ppat.1004995 PMID: 26098424
9. Liang B., Li Z., Jenni S., Rahmeh A.A., Morin B.M., Grant T., et al. (2015) Structure of the L Protein of Vesicular Stomatitis Virus from Electron Cryomicroscopy. Cell 162: 314-327 10.1016/j.cell.2015.06.018 PMID: 26144317
10. Kallberg M., Wang H., Wang S., Peng J., Wang Z., Lu H., et al. (2012) Template-based protein structure modeling using the RaptorX web server. Nat Protoc 7: 1511-1522 10.1038/nprot.2012.085 PMID: 22814390
11. Noton S.L., Nagendra K., Dunn E.F., Mawhorter M.E., Yu Q., Fearns R. (2015) Respiratory Syncytial Virus Inhibitor AZ-27 Differentially Inhibits Different Polymerase Activities at the Promoter. J Virol 89: 7786-7798 10.1128/JVI.00530-15 PMID: 25995255
12. Tiong-Yip C.L., Aschenbrenner L., Johnson K.D., McLaughlin R.E., Fan J., Challa S., et al. (2014) Characterization of a respiratory syncytial virus L protein inhibitor. Antimicrob Agents Chemother 58: 3867-3873 10.1128/AAC.02540-14 PMID: 24777090
13. Chou T.C. (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446 10.1158/0008-5472.CAN-09-1947 PMID: 20068163
14. Chou T.C., Talalay P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55 PMID: 6382953
15. Prichard M.N., Shipman Jr. C. (1990) A three-dimensional model to analyze drug-drug interactions. Antiviral Res 14: 181-205 PMID: 2088205
16. Gomez R.S., Guisle-Marsollier I., Bohmwald K., Bueno S.M., Kalergis A.M. (2014) Respiratory Syncytial Virus: pathology, therapeutic drugs and prophylaxis. Immunol Lett 162: 237-247 10.1016/j.imlet.2014.09.006 PMID: 25268876
17. Morin B., Kranzusch P.J., Rahmeh A.A., Whelan S.P. (2013) The polymerase of negative-stranded RNA viruses. Curr Opin Virol 3: 103-110 10.1016/j.coviro.2013.03.008 PMID: 23602472
18. Li J., Rahmeh A., Morelli M., Whelan S.P. (2008) A conserved motif in region v of the large polymerase proteins of nonsegmented negative-sense RNA viruses that is essential for mRNA capping. J Virol 82: 775-784 PMID: 18003731
19. Ogino T., Banerjee A.K. (2007) Unconventional mechanism of mRNA capping by the RNA-dependent RNA polymerase of vesicular stomatitis virus. Mol Cell 25: 85-97 PMID: 17218273
20. Ogino T., Yadav S.P., Banerjee A.K. (2010) Histidine-mediated RNA transfer to GDP for unique mRNA capping by vesicular stomatitis virus RNA polymerase. Proc Natl Acad Sci U S A 107: 3463-3468 10.1073/pnas.0913083107 PMID: 20142503
21. Lam A.M., Edwards T.E., Mosley R.T., Murakami E., Bansal S., Lugo C., et al. (2014) Molecular and structural basis for the roles of hepatitis C virus polymerase NS5B amino acids 15, 223, and 321 in viral replication and drug resistanceAntimicrob Agents Chemother 58: 6861-6869 10.1128/AAC.03847-14 PMID: 25182647
22. Lam A.M., Espiritu C., Bansal S., Micolochick Steuer H.M., Zennou V., Otto M.J., et al. (2011) Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA. J Virol 85: 12334-12342 10.1128/JVI.05639-11 PMID: 21957306
23. Jin Z, Leveque V, Ma H, Johnson KA, Klumpp K (2013) NTP-mediated nucleotide excision activity of hepatitis C virus RNA-dependent RNA polymerase. Proc Natl Acad Sci U S A 110: E348-357 10.1073/pnas.1214924110 PMID: 23307808
24. Meyer P.R., Matsuura S.E., So A.G., Scott W.A. (1998) Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci U S A 95: 13471-13476 PMID: 9811824
25. Sudo K., Miyazaki Y., Kojima N., Kobayashi M., Suzuki H., Shintani M., et al. (2005) YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of actionAntiviral Res 65: 125-131 PMID: 15708639
26. Sluis-Cremer N., Temiz N.A., Bahar I. (2004) Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res 2: 323-332 PMID: 15544453
27. Biswal B.K., Cherney M.M., Wang M., Chan L., Yannopoulos C.G., Bilimoria D., et al. (2005) Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J Biol Chem 280: 18202-18210 PMID: 15746101
28. Boyce S.E., Tirunagari N., Niedziela-Majka A., Perry J., Wong M., Kan E., et al. (2014) Structural and regulatory elements of HCV NS5B polymerase - beta-loop and C-terminal tail - are required for activity of allosteric thumb site II inhibitorsPLoS One 9: e84808 10.1371/journal.pone.0084808 PMID: 24416288
29. Mosley R.T., Edwards T.E., Murakami E., Lam A.M., Grice R.L., Du J., et al. (2012) Structure of hepatitis C virus polymerase in complex with primer-template RNA. J Virol 86: 6503-6511 10.1128/JVI.00386-12 PMID: 22496223
30. Li J., Johnson K.A. (2016) Thumb Site 2 Inhibitors of Hepatitis C Viral RNA-Dependent RNA Polymerase Allosterically Block the Transition from Initiation to Elongation. J Biol Chem
31. Noton S.L., Deflube L.R., Tremaglio C.Z., Fearns R. (2012) The respiratory syncytial virus polymerase has multiple RNA synthesis activities at the promoter. PLoS Pathog 8: e1002980 10.1371/journal.ppat.1002980 PMID: 23093940
32. Hotard A.L., Shaikh F.Y., Lee S., Yan D., Teng M.N., Plemper R.K., et al. (2012) A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 434: 129-136 10.1016/j.virol.2012.09.022 PMID: 23062737
33. Fearns R., Peeples M.E., Collins P.L. (2002) Mapping the transcription and replication promoters of respiratory syncytial virus. J Virol 76: 1663-1672 PMID: 11799161
34. Noton S.L., Cowton V.M., Zack C.R., McGivern D.R., Fearns R. (2010) Evidence that the polymerase of respiratory syncytial virus initiates RNA replication in a nontemplated fashion. Proc Natl Acad Sci U S A 107: 10226-10231 10.1073/pnas.0913065107 PMID: 20479224
35. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., et al. (2004) UCSF Chimera - a visualization system for exploratory research and analysis. J Comput Chem 25: 1605-1612 PMID: 15264254